Autopsy report · NCT00165087

Treatment of Childhood Acute Lymphoblastic Leukemia

“Terminated by IRB for continuing review”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 years 8 months after it had already started.
• Ran for about 10 years 8 months before it stopped.
• 491 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Dana-Farber Cancer Institute

Sponsor type

University, hospital or other

Conditions

Acute Lymphoblastic Leukemia

Interventions

asparaginase (E. Coli); asparaginase (Erwina); dexrazoxane; doxorubicin; cranial radiation (once daily fractionation); cranial radiation (twice-daily fractionation)

Participants

491

Sites

10

Countries

Canada, Puerto Rico, United States

Trials that died the same way

• Transcranial Infrared Laser Stimulation (TILS) of Prefrontal Cognition in Post-traumatic Stress Disorder (PTSD)
  “IRB approval terminated” (85% match in meaning)
• Adherence to Otezla
  “Terminated IRB approval 6/26/2024, study was never initiated or activated” (75% match in meaning)
• ASTHMAXcel Emergency Department Study
  “IRB approval expired” (72% match in meaning)
• Impact of Cardiac Resynchronization Therapy on Right Ventricular Function in Left Ventricular Assist Device Patients
  “IRB Approval withdrawn” (72% match in meaning)
• Feasibility of Ultra-sound Guided Radiofrequency Ablation in the Management of Head and Neck Neoplasia.
  “Administratively withdrawn by the IRB prior to IRB approval” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.